StemCellPatents.com Newsletter
Your weekly source for the latest stem cell research and stem cell patents.
Hello manoj kumar valluru,
Yes, you read correctly, a report last week from Hadassah in PloS One claims that ES generated neural progenitors inhibit experimental allergic encephalomyelitis (EAE) by means of immune modulation, not remyelination. There was another story from last week that may be of interest. Generally, when we go to business development conferences people talk about immune therapy for cancer being dead and that small molecules are the way to go. Not so, last week peptides were identified from the Aurora kinase that make leukemic cells selectively immunogenic but not control hematopoietic stem cells. Hopefully once we overcome the issues of tumor induced immune suppression we will be able to generate vaccines against cancer stem cells.
Some neat patents got issued last week. 7,429,383 covers pretty much any parathyroid hormone associated hematopoietic stem cell expansion and mobilization. Since parathyroid hormone receptor agonists are already clinically approved (FORTEO: teriparatide) for other indications, and clinical data exists supporting the patent, this piece of IP could be very valuable. Another patent (7,429,489) issued last week covered the use of chelation for ex vivo expansion of hematopoietic stem cells
Now we have to apologize...last week, we experienced some technical issues that resulted in us being unable to get our newsletter sent out....so, below are the happenings from the previous week.
You may get a kick out of a patent issued (# 7,427,502) which covers methods of identifying stem cells based on the shape of their nucleus. Of therapeutic interest, the use of secretoneurin, a 33 amino acid peptide was covered in a patent (# 7,427,597) for preventing stroke damage. While the patent covers intracerebral delivery, the authors published that systemic administration not only induces stem cell mobilization but also is beneficial in the middle cerebral artery ligation. This peptide seems interesting since its expression is induced by hypoxia, in part via HIF-1 alpha.
Speaking of therapeutics, the company Stemline was issued a patent (# 7,427,400) covering antibodies to glypican-3 and tie-1 as means of inhibiting tumor stem cells.
A new method of expanding hematopoietic stem cells by the use of the transcription factor CDX-4 was patented (# 7,427,603). The question is how will we get it selectively into the cells?
In terms of academic publications, Darwin Prockup published a very neat way of selecting for "potent" mesenchymal stem cells in a PNAS paper.
|
|
|
|
Thanks again for your help in supporting StemCellPatents.com.
RMSC 2008 World Congress
The 3rd Annual Stem Cells World Congress
The Stem Cell Meeting
Media Partnerships
We welcome your comments and suggestions! Tell us here.
(BETA)